Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 568-576

  Flaherty, Keith T ^a,e   LoRusso, Patricia M ^b   DeMichele, Angela ^a   Abramson, Vandana G ^a,f   Courtney, Rachel ^c   Randolph, Sophia S ^c   Shaik, M Naveed ^c   Wilner, Keith D ^c   O'Dwyer, Peter J ^a   Schwartz, Gary K ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; RETINOBLASTOMA PROTEIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHASIA; DYSPNEA; FAILURE TO THRIVE; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HIP ARTHROPLASTY; HUMAN; HYPONATREMIA; LEUKOPENIA; MALE; NAUSEA; NECK PAIN; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PIPERAZINES; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855983664     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0509     Document Type: Article

References (25)

1. Harbour JW, Luo RX, Dei SA, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98: 859-69. (Pubitemid 29446902)
2. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108. (Pubitemid 26099813)
3. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007;98:629-35. (Pubitemid 46563437)
4. Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23:6364-9. (Pubitemid 46218848)
5. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007;17:60-5. (Pubitemid 46109297)
6. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
7. Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005;65:11345-53. (Pubitemid 41821691)
8. Leonard JP, LaCasce A, Smith MR, Noy A, Yap JT, Van den Abbeele AD, et al. Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma. Blood (ASH Annu Meet Abstr) 2008;112:Abstr 264.
9. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626-36. (Pubitemid 47105508)
10. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997;15:3301-12. (Pubitemid 27485848)
11. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
12. Berthet C, Kaldis P. Cell-specific responses to loss of cyclin-dependent kinases. Oncogene 2007;26:4469-77. (Pubitemid 47037044)
13. Schwartz GK, Lorusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011;104:1862-8.
14. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13: 176-81. (Pubitemid 36962641)
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
16. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-72. (Pubitemid 35435525)
17. Shapiro GI, Bannerji R, Small K, Black S, Statkevich P, Abutarif M, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3532).
18. Tibes R, Jimeno A, Von Hoff DD, Walker R, Paccarini MA, Scaburri A, et al. Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3531).
19. Mahadevan D, Plummer R, Squires MS, Rensvold D, Dragovich T, Adams J, et al. A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3533).
20. Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 2003;9:5195-204. (Pubitemid 37413569)
21. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008;26:59-65.
22. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K, et al. Treatment of growing teratoma syndrome. N Engl J Med 2009;360: 423-4.
23. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010;28: 3015-22.
24. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000;18:371-5. (Pubitemid 30056427)
25. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002;20:4713-21. (Pubitemid 36025290)